Savient re-evaluating prosaptide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Savient is terminating a Phase II study of prosaptide in HIV patients with peripheral neuropathic pain, the firm says March 11. "Over the next few months," Savient will decide whether it "will pursue alternative analgesia indications, or further explore the potential of prosaptide to treat peripheral neuropathy in HIV/AIDS and other diseases." Savient said the trial was stopped due to a low probability for attaining statistical significance for the analgesia efficacy endpoint. Prosaptide reached Phase II for diabetic peripheral neuropathy, but Savient decided to focus on peripheral neuropathy associated with HIV/AIDS...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.